Table 31Characteristics of included placebo-controlled trials of SNRIs

StudyArm Dose mg/day (N)Duration (Weeks)Population Trauma TypeBaseline PTSD SeverityaMean Age (Y)% F% Non-whiteRisk of Bias
Davidson et al., 2006173Venlafaxine ER (37.5 to 300) (161)
Placebo (168)
24Male and female
Mixed
81 to 82.94154NRMedium
Davidson et al., 2006133Total (538)b
Venlafaxine (37.5 to 375) (179)
Sertraline (25 to 200) (173)
Placebo (179)
12Male and female
Mixed
~82NRNRNRMedium

CAPS = Clinician Administered PTSD Scale; F = female; mg = milligram; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; y = year

a

Data reported are mean CAPS or range of mean CAPS scores across groups unless another instrument is specified.

b

The Ns for each are the number analyzed; the number randomized to each group was not reported (overall N was 538; 531 were included in the analysis).

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.